163 related articles for article (PubMed ID: 21172012)
1. Does the development of new medicinal products in the European Union address global and regional health concerns?
Catalá-López F; García-Altés A; Alvarez-Martín E; Gènova-Maleras R; Morant-Ginestar C
Popul Health Metr; 2010 Dec; 8():34. PubMed ID: 21172012
[TBL] [Abstract][Full Text] [Related]
2. [The use of nanotechnology in medicinal products in the light of European Union law].
Jurewicz M
Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580
[TBL] [Abstract][Full Text] [Related]
3. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
4. New Information on Old Medicinal Products: A Cross-Sectional Analysis of Guidance for Paediatric Use for Substances on the European Priority List of Off-Patent Medicinal Products.
Mogensen AB; Christiansen H; De Bruin ML; Hallgreen CE
Paediatr Drugs; 2022 Nov; 24(6):679-687. PubMed ID: 35962257
[TBL] [Abstract][Full Text] [Related]
5. Medicinal plants and their preparations in the European market: Why has the harmonization failed? The cases of St. John's wort, valerian, ginkgo, ginseng, and green tea.
Bilia AR; Costa MDC
Phytomedicine; 2021 Jan; 81():153421. PubMed ID: 33291029
[TBL] [Abstract][Full Text] [Related]
6. Regulation of immunological veterinary medicinal products in the European Union.
Brunko P
Rev Sci Tech; 1995 Dec; 14(4):1133-41. PubMed ID: 8639951
[TBL] [Abstract][Full Text] [Related]
7. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
8. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study.
Murray CJ; Lopez AD
Lancet; 1997 May; 349(9063):1436-42. PubMed ID: 9164317
[TBL] [Abstract][Full Text] [Related]
9. European Medicines Agency support mechanisms fostering orphan drug development.
Butlen-Ducuing F; Rivière F; Aarum S; Llinares-Garcia J
Drug News Perspect; 2010; 23(1):71-81. PubMed ID: 20155221
[TBL] [Abstract][Full Text] [Related]
10. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union.
Vlietinck A; Pieters L; Apers S
Planta Med; 2009 Jun; 75(7):683-8. PubMed ID: 19204891
[TBL] [Abstract][Full Text] [Related]
11. Changing paradigms in bioequivalence trials submitted to the EMA for evaluation - A clinical and regulatory perspective.
Refalo N; Chetcuti D; Tanti A; Serracino-Inglott A; Borg JJ
Saudi Pharm J; 2017 Feb; 25(2):280-289. PubMed ID: 28344480
[TBL] [Abstract][Full Text] [Related]
12. Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit.
Mulder J; Teerenstra S; van Hennik PB; Pasmooij AMG; Stoyanova-Beninska V; Voest EE; de Boer A
ESMO Open; 2023 Apr; 8(2):101209. PubMed ID: 37054504
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life and other patient-reported outcomes in the European centralized drug regulatory process: a review of guidance documents and performed authorizations of medicinal products 1995 to 2003.
Szende A; Leidy NK; Revicki D
Value Health; 2005; 8(5):534-48. PubMed ID: 16176492
[TBL] [Abstract][Full Text] [Related]
14. EMEA and Gene Therapy Medicinal Products Development in the European Union.
Papaluca Amati M; Pignatti F; Nolte A; Amerasinghe N; Gustafsson D; Moulon I; Le Courtois P
J Biomed Biotechnol; 2003; 2003(1):3-8. PubMed ID: 12686717
[TBL] [Abstract][Full Text] [Related]
15. [Registration of new medicinal products in Europe].
Singer E
Onkologie; 2008; 31 Suppl 2():64-6. PubMed ID: 18487872
[TBL] [Abstract][Full Text] [Related]
16. Disease burden metrics and the innovations of leading pharmaceutical companies: a global and regional comparative study.
Jung YL; Hwang J; Yoo HS
Global Health; 2020 Sep; 16(1):80. PubMed ID: 32912258
[TBL] [Abstract][Full Text] [Related]
17. Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network.
Heard JM; Vrinten C; Schlander M; Bellettato CM; van Lingen C; Scarpa M;
Orphanet J Rare Dis; 2020 Jan; 15(1):3. PubMed ID: 31907071
[TBL] [Abstract][Full Text] [Related]
18. Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera.
Watanabe N; Yano K; Tsuyuki K; Okano T; Yamato M
Mol Ther Methods Clin Dev; 2015; 2():14066. PubMed ID: 26052534
[TBL] [Abstract][Full Text] [Related]
19. Overview of the European regulatory approval system.
Pignatti F; Boone H; Moulon I
J Ambul Care Manage; 2004; 27(2):89-97. PubMed ID: 15069985
[TBL] [Abstract][Full Text] [Related]
20. Legal instruments supporting the development of orphan medicinal products in the European Union.
Miaskowska-Daszkiewicz K
Acta Pol Pharm; 2014; 71(1):181-7. PubMed ID: 24779206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
